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Abstract
Alternative splicing is the post-
transcriptional process by which a single
gene can produce multiple transcripts and
thereby protein isoforms. The presence of
different transcripts of a gene across samples
can be analysed by whole-transcriptome mi-
croarrays. Reproducing results from published
microarray data represents a challenge due
to the vast amounts of data and the large
variety of pre-processing and filtering steps
employed before the actual analysis is carried
out. To ensure a firm basis for methodological
development where results with new methods
are compared with previous results it is crucial
to ensure that all analyses are completely
reproducible for other researchers.
We here give a detailed workflow on
how to perform reproducible analysis of
the GeneChip R© Human Exon 1.0 ST Ar-
ray at probe and probeset level solely in
R/Bioconductor, choosing packages based on
their simplicity of use. To exemplify the use
of the proposed workflow we analyse differen-
tial splicing and differential gene expression in
a publicly available dataset using various stat-
istical methods.
We believe this study will provide other re-
searchers with an easy way of accessing gene ex-
pression data at different annotation levels and
with the sufficient details needed for developing
their own tools for reproducible analysis of the
GeneChip R© Human Exon 1.0 ST Array.
Contact: maria@math.aau.dk
1 Introduction
In the field of microarrays it has traditionally been
difficult to compare new methods to methods in pub-
lished papers as the many methods available for pre-
processing, summarizing and filtering make it almost
impossible to work with the exact same data, even
when the raw data is made available. That is why we
consider reproducible research fundamental as it will
facilitate easy 1) revision of papers, 2) access to data
and results, 3) communication to other researchers
and 4) comparison between different methods. Re-
producible research is gaining relevance among the
scientific community as shown by the number of pa-
pers published on the subject during the last years
[2, 3, 4]. Ioannidis et al. showed that the res-
ults of only 2 out of 18 published microarray gene-
expression analyses were completely reproducible [5].
This is why some authors demand that document-
ation and annotation, database accessions and URL
links and even scripts with instructions are made pub-
licly available [2]. Journals like Biostatistics have
even appointed an Associate Editor for reproducible
research, but still treat it as a “desirable goal” rather
than a requirement [6]. Setting up a framework
for reproducible research necessarily implies working
with free and open-source software as for example
R/Bioconductor [7, 8]. Additionally, using Sweave
[9] (a tool for embedding R code in LATEXdocuments
[11]), enables automatic reports that can be updated
with output from the analysis.
The main tool in this paper will be the Biocon-
ductor package aroma.affymetrix [12] that can
analyse all Affymetrix chip types with a (.CDF)
Chip Definition File. The number of arrays
(samples) that can be simultaneously analysed by
aroma.affymetrix is virtually unlimited as the sys-
tem requirements are just 1GB RAM, for any operat-
ing system [13]. This package is freely available and
can easily be installed into R. The aroma.affymetrix
website www.aroma-project.org is conceived as ref-
erence for all the possible microarrays that can be
analysed with aroma.affymetrix, and does not fo-
cus specifically on the analysis of the GeneChip R©
Human Exon 1.0 ST Array (or exon array in short).
Portable scripts for a fast and basic analysis can be
obtained on request to aroma.affymetrix’s authors.
The analysis of exon array data in R/Bioconductor
is not yet standard. There are several packages
available, and it can be a tremendous effort for
a newcomer to maneuver between them, and to
overcome the numerous challenges associated with
these packages. This paper aims to make this task
easier and to provide a quick reference guide to
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aroma.affymetrix’s documentation. We also ex-
plain how to extract data for different statistical ana-
lyses and propose a method for gene annotation and
for gene profile visualization. For this last step, we
use the packages biomaRt and GenomeGraphs to an-
notate and visualize the transcripts in a genomic con-
text.
The analysis workflow presented in this paper is
carried out solely in R/Bioconductor, and the paper
is available as a Sweave (.Snw) document that will
allow the reader to reproduce our exact results. The
.Snw document can also be converted into an R script
and executed. The workflow starts by reading in the
data, followed by background correction and quantile
normalization. We then explain how to obtain tran-
script cluster -, probeset -, and probe-level estimates.
Afterwards, different methods for the statistical ana-
lysis of differential splicing or differential gene expres-
sion are reviewed. Finally, we make a suggestion on
how to annotate transcript clusters to genes in the
lists obtained from the statistical analyses, and how
to plot the data including genomic information. To
exemplify the use of the workflow, an example data-
set [14] is analysed along the way.
2 Background on alternative
splicing
Splicing is the post-transcriptional process that gen-
erates mature eukaryotic mRNAs from pre-mRNAs
by removing the non-coding intronic regions and join-
ing together the exonic coding regions. For many
genes, two or more splicing events take place during
maturation of mRNA molecules resulting in a cor-
responding number of alternatively spliced mRNAs.
These mature mRNAs translate into protein isoforms
differing in their amino acid sequence and ultimately
in their biochemical and biological properties [15, 16].
Alternative splicing is one of the main tools for gen-
erating RNA diversity, contributing to the diverse
repertoire of transcripts and proteins [16, 17]. It is
known that 92-94% of multi-exon human genes are
alternatively spliced and that 85% of those have a
minor isoform frequency of at least 15% [18, 19]. In
our case we will focus on the detection of differential
splicing between groups, as for instance tissue types,
or healthy vs. diseased samples.
The exon array was presented in October 2005
as a tool for the analysis and profiling of whole-
transcriptome expression [20, 21, 22]. To interrogate
each potential exon with at least one probeset, the
exon array contains about 5.6 million probes grouped
into more than 1.4 million probesets (most probesets
consisting of 4 probes), which are further grouped
into 1.1 million exon clusters, or collections of over-
lapping exons. Finally, exon clusters are grouped into
over 300.000 transcript clusters to describe their re-
lationship, as for example shared splice sites or over-
lapping exonic sequences. Each gene is covered, on
average, by 40 probes interrogating regions located
along the entire gene [23]. This probe positioning
aims at providing better estimates of gene expression
levels than previous arrays, and allows for the study
of differential splicing [24] and differential gene ex-
pression based on summarized exon expression.
The exon array has three levels of annotation for
the interrogated transcript clusters: core, extended
and full [25]. Core transcript clusters are suppor-
ted by the most reliable evidence such as RefSeq
transcripts and full-length mRNAs [26] and a core
transcript cluster is roughly a gene [27]; the exten-
ded level contains the core transcript clusters plus
cDNA-based annotations [28] and the full level con-
tains the two previous levels plus ab-initio, or al-
gorithmic, gene predictions [29]. It is worth noting
that aroma.affymetrix enables the analysis at the
three levels of annotation mentioned above, and also
that it provides intensity estimates for probes, probe-
sets and transcript clusters, allowing for a variety of
options for the analysis.
3 Workflow
Our workflow for the analysis of exon array data
starts setting up the required folder structure for
aroma.affymetrix. The data is then preprocessed
and summarised at transcript cluster and/or probe-
set level. Next, transcript clusters are analysed with
several statistical models to detect differential expres-
sion or splicing and the transcripts of interest are an-
notated and visualised at the end, see Figure 1. In the
code, places where user input is needed are marked by
“***”, and places where the user can choose whether
to modify parameters are marked by “**”.
To exemplify the use of the tutorial we have used
Affymetrix’s colon cancer data set [14], consisting of
a collection of paired samples of colon tumour tissue
and adjacent normal tissue from 10 patients and
available at http://www.affymetrix.com/support/
technical/sample_data/exon_array_data.affx.
According to Affymetrix’s website, the RNA samples
are from a commercial source. This dataset has been
used in a number of papers to evaluate the perform-
ance of different analysis methods [30, 31, 32, 33] and
a number of genes have been validated to present
differential splicing or not [14]. The analysis was
done in R version 2.15.1 (32 bit).
Start by installing and loading aroma.affymetrix
in R and loading the other libraries required:
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Figure 1: Flowchart for an analysis with aroma.affymetrix, read counter-clockwise starting in upper left
corner: 1. and 2. folder structure set-up including library, annotation and .CEL files, 3. data pre-processing
and summarization, 4. extraction of intensities at transcript cluster, probeset and probe level, including
filtering recommended by Affymetrix, 5. statistical analysis of differentially expressed or spliced transcript
clusters and 6. annotation and visualization of transcript cluster profiles. Blue boxes represent parts of
the analysis implemented in aroma.affymetrix, yellow and green boxes are part of the code provided in
this paper, and purple boxes represent user-input needed. Output produced at several steps is saved in
user-chosen ”output.folder” and represented by a star shape in the workflow. A number of folders are
automatically generated by aroma.affymetrix - represented by a faded yellow rectangle in 3. -, our workflow
does not make use of the contents of such folders.
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> source("http://aroma-project.org/hbLite.R")
> hbInstall("aroma.affymetrix")
> require(aroma.affymetrix)
> require(biomaRt)
> require(GenomeGraphs)
3.1 Setting up the structure and files
for the analysis workflow
This section corresponds to steps 1. and 2.
in Figure 1. The first step is to create the
folder structure: under a main folder of our
choice - “myworkingDirectory” - we will cre-
ate the “rawData” and “annotationData” folders,
which will be common to all aroma.affymetrix
projects. Inside “annotationData”, the subfolder
“chipTypes” will contain one subfolder per chip type,
with the exact name of the .CDF file provided by
Affymetrix, “HuEx-1 0-st-v2” in our case. Inside
this folder we will save any library and annotation
files that might be needed. Besides, the “myDataSet”
folder will be created under “rawData” to store .CEL
files. These files are the output of a microarray ex-
periment and contain the result of the intensity calcu-
lations per probe or pixel. Note that the microarray
experiment produces one .CEL file per array and that
one array analyses one sample. Affymetrix sometimes
refer to their microarrays as “chips”. Note also that
we need one “myDataSet” folder per experiment and
that “myDataSet” will be added as a tag at the end
of the aroma.affymetrix output.
> #*** user-defined working directory
> wd <- "myWorkingDirectory"
> #*** user-defined data set name
> ds <- "myDataSet"
In the second step we save our library (Chip
Definition File (.CDF) in our case) and .CEL
files in the corresponding folders. Affymetrix’s
unsupported .CDF files can be downloaded
from http://www.affymetrix.com/Auth/support/
downloads/library_files/HuEx-1_0-st-v2.cdf.zip,
note that registration is needed. For the exon array,
Elizabeth Purdom has created a number of binary
.CDF files based on Affymetrix’s text .CDF file
[13] that are faster to query and more memory
efficient. Such binary .CDF files for core, extended
and full sets of probesets can be downloaded from
http://aroma-project.org/node/122. In the
example below we use the custom aroma file for core
transcript clusters, which might be updated in the
future. Our original .CEL files will be copied from
the user-specified “myCELfileDirectory” into the
exon “rawData” subfolder (the code is part of the
.Snw version of this paper). The desired output
folder specified in “output.folder” should exist in
advance.
> #** download user-defined library file
> library.file <-
+ paste(annotation.data.exon,
+ "HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf",
+ sep = "/")
> download.address <-
+ "http://bcgc.lbl.gov/cdfFiles/"
> file <- paste("HuEx-1_0-st-v2,A20071112,EP",
+ "HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf",
+ sep = "/")
> custom.cdf <-
+ paste(download.address, file, sep = "")
> download.file(url = custom.cdf,
+ destfile = library.file,
+ mode = "wb", quiet = FALSE)
> #*** user-defined directory containing .CEL files
> cel.directory <- "myCELfileDirectory"
> #*** user-defined output folder
> output.folder <- "output.folder"
Besides, the sample information should be saved
in a tab separated file with column names
celFile, replicate, and treatment containing
.CEL file name (without .CEL), replicate identi-
fier and treatment name, respectively. This file
should be called ”SampleInformation.txt” and it
will be copied from the user-specified directory into
the "\rawData\myDataSet \HuEx-1 0-st-v2" folder
(which will also contain the .CEL files) after it has
been created. The sample information file for the
colon cancer example is attached as an additional file.
> sample.info <-
+ read.table(file = paste(raw.data.exon,
+ "SampleInformation.txt", sep = "/"),
+ sep = "\t", header = TRUE)
Finally, NetAffx transcript clusters’ and
probesets’ annotation files should be saved in
“annotationData/chipTypes/” “HuEx-1 0-st-v2”.
We have used release 32, which was most up to
date at the time of writing and we downloaded files
“HuEx-1 0-st-v2.na32.hg19.transcript.csv.zip” and
“HuEx-1 0-st-v2.na32.hg19.probeset.csv.zip” from
http://www.affymetrix.com/estore/browse/products.
jsp?productId=131452&categoryId=35676&productName=
GeneChip-Human-Exon-ST-Array#1_3, Technical Docu-
mentation tab, under NetAffx Annotation Files. The
extracted .csv files should be converted into .Rdata
files for querying them faster in the future. Note
that the number of lines to skip might differ for
future annotation files.
> transcript.clusters.NetAffx.32 <-
+ read.csv(file = paste(annotation.data.exon,
+ "HuEx-1_0-st-v2.na32.hg19.transcript.csv",
+ sep = "/"), skip=24)
> probesets.NetAffx.32 <-
+ read.csv(file = paste(annotation.data.exon,
+ "HuEx-1_0-st-v2.na32.hg19.probeset.csv",
+ sep = "/"), skip=23)
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3.2 Data pre-processing and sum-
marization to probeset/transcript
cluster level
After defining chip type and dataset, background cor-
rection and quantile normalization are carried out as
shown in Figure 1, step 3. In these pre-processing
steps, it is possible to use either Affymetrix’s ori-
ginal .CDF file, the .CDF files provided by the
aroma project (the file for core transcript clusters in
our example), or a .CDF file created by the user.
The summarization step, however, must be done us-
ing one of the custom .CDF files available at the
aroma.affymetrix project website.
Background correction as defined by Ir-
izarry [34] and quantile normalization are per-
formed by the RmaBackgroundCorrection() and
QuantileNormalization() functions, respectively.
The raw, background corrected and quantile nor-
malized probe intensities can be visualized using
the plotDensity() function applied to the cor-
responding object. Summarization is done with
the ExonRmaPlm function [35]. The parameter
mergeGroups determines whether to summarize at
transcript level (TRUE) or probeset level (FALSE).
All the functions described automatically create
subfolders such as “plmData” or “probeData” inside
“myWorkingDirectory”. A more detailed version
of this code with interesting comments about the
choice of .CDF and possibilities for quality control
is available at http://www.aroma-project.org/
vignettes/FIRMA-HumanExonArrayAnalysis.
> chipType <- "HuEx-1_0-st-v2"
> #** user-defined .CDF file: change tags parameter
> cdf <- AffymetrixCdfFile$byChipType(chipType,
+ tags = "coreR3,A20071112,EP")
> cs <- AffymetrixCelSet$byName(ds, cdf = cdf)
>
> # background correction
> bc <- RmaBackgroundCorrection(cs)
> csBC <- process(bc, verbose = verbose)
>
> # quantile normalization
> qn <- QuantileNormalization(csBC,
+ typesToUpdate = "pm")
> csN <- process(qn, verbose = verbose)
>
> # summarization
> # transcript cluster level
> plmTr <- ExonRmaPlm(csN, mergeGroups = TRUE,
+ tag = "coreProbesetsGeneExpression")
> # probeset/exon level
> plmEx <- ExonRmaPlm(csN, mergeGroups = FALSE,
+ tag = "coreProbesetsExonExpression")
3.3 Extraction of intensity estimates
The aroma.affymetrix documentation focuses on
analyses at the probeset and transcript cluster levels.
The respective intensities are obtained by apply-
ing the function getChipEffectSet() to the tran-
script or probeset plm objects (plmTr and plmEx,
respectively) and then extracting the correspond-
ing dataframes. However, it is also possible to ex-
tract the background corrected and quantile nor-
malized intensities of all probes using the function
getUnitIntensities. While plmTr is suitable for
the FIRMA analysis (3.4), plmEx is well suited for
probeset-level analysis. For the linear model ana-
lysis described in Section 3.4 we have created one list
of dataframes containing probe intensities per tran-
script cluster, and another list of dataframes contain-
ing probeset intensities per cluster (code included in
.Snw).
> # extract a matrix of gene intensities
> cesTr <- getChipEffectSet(plmTr)
> trFit <- extractDataFrame(cesTr, addNames=TRUE)
> # extract a matrix of probeset intensities
> cesEx <- getChipEffectSet(plmEx)
> exFit <- extractDataFrame(cesEx, addNames=TRUE)
> # extract a list of probe intensities per gene
> unitIntensities <-
readUnits(csN, verbose=verbose)
The high number of transcript clusters analysed in
combination with the usually small number of chips
tends to cause a high number of false positives [25].
In order to reduce the number of false positives, Affy-
metrix recommends to perform detection above back-
ground (DABG) [36] on the dataset prior to the ana-
lysis [25]. The DABG procedure is not implemented
in aroma.affymetrix, so we decided to follow the
procedure described in [30] and use 3 as a threshold
for the probeset intensity, so that probesets with a
log2 intensity below 3 will be marked as absent. Ex-
cept for this change, we followed the guidelines pro-
posed in [25] to remove absent transcript clusters and
probesets, where neither probesets that are absent in
more than half of the samples of a group nor tran-
script clusters with more than half of the probesets
absent are analysed.
Besides this filtering based on expression levels,
another filtering that removes probesets presenting
cross-hybridization is also advisable [25]. Cross-
hybridising probesets are identified in file ”HuEx-1 0-
st-v2.na32.hg19.probeset.csv” and removed. Affyme-
trix recommends to filter them out after the analysis,
but we have decided not to include them in the ana-
lysis in order to narrow down the number of probe-
sets/transcript clusters to investigate.
The filtering procedure is part of the .Snw file. In
our example, where we analysed only core probesets,
136233 probesets out of 284258 were deemed present
by our filter, and the number of transcript clusters to
analyse (present in both samples) was reduced from
18708 to 8401.
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3.4 Statistical analysis
In this section we give an overview of model-based
statistical methods available for the analysis of differ-
ential splicing and suggest a method for the analysis
of differential gene expression.
3.4.1 Differential splicing
The analyses carried out in this paper are model-
based approaches, and the analysis of differential spli-
cing is done genewise. The models we use are exten-
sions of the linear model by Li and Wong [37]
ypt = αp + βt + εpt, (1)
where ypt is the intensity measure of probe p for treat-
ment t, αp is a probe affinity term, βt is the gene-level
estimate for treatment t, and εpt is the error term.
ANOSVA (Analysis of Splicing Variation) was
presented by Cline et al. [38] and is a two-way AN-
OVA model with probeset and treatment as factors:
ypet = µ+ αe + βt + γet + εpet, (2)
where ypet is the intensity measure of probe p in
probeset e and treatment t, the overall mean µ is the
baseline level of all probes in all experiments, and αe
and βt are the probeset and treatment effects. The
interaction term γet tells whether the effect of the
probeset depends on the treatment and is therefore
key to the detection of differential splicing.
The model in (2) can be extended to include ran-
dom effects associated to replications from the same
individual, r:
ypetr = µ+ αe + βt + γet + Ir + Ctr + εpetr, (3)
where Ir is the random effect of each individual r and
Ctr is the random chip effect. The error terms εpetr
are i.i.d. N(0, σ2)-distributed.
Under the null-hypothesis of no differential spli-
cing, the γet’s will all be zero, therefore we consider
the test statistic
tet =
γˆet
σˆ
,
where γˆet is the estimate for γet, and σˆ is the stand-
ard error of γˆet. Large values will be critical for the
null hypothesis. Under the model assumptions, t will
follow a tN−T ·(ne+R−1) distribution [39, Chap. 5],
with N the total number of observations per tran-
script cluster, T the number of treatments, ne the
number of probesets in the transcript cluster and R
the number of individuals. For each gene, the smal-
lest p-value from the above t-tests is regarded as a
measure of confidence that the gene is differentially
spliced across the experimental conditions [38]. The
interaction estimates and variances and thus the test
statistics are contrast-dependent, so choosing a differ-
ent contrast will alter the gene lists. In our analysis,
we have used the sum contrast available in R, where
parameter estimates are centred around zero.
A package in R for fitting linear and generalized lin-
ear mixed-effects models is lme4 [52]. Linear mixed-
effects models can also be analysed using lm, which
is faster but requires a balanced design. In our ex-
ample dataset we use lm to fit the model in equa-
tion (3) to the probe level estimates obtained us-
ing unitIntensities() from aroma.affymetrix to
8075 multiexonic transcript clusters. Here, we only
show the code corresponding to equation (3), the rest
of the code is part of the .Snw file.
> # ** user-defined parameters for linear model
> lm <-
+ lm(intensity ˜ probeset + treatment +
+ C(probeset:treatment, contr.sum) +
+ replicate/treatment)
> n.probesets <- length(unique(dataframe$probeset))
> main.effects <-
+ 1 + (n.probesets - 1) +
+ (length(unique(dataframe$treatment)) - 1)
> DS.parameters <- (n.probesets - 1)*
+ (length(unique(dataframe$treatment)) - 1)
> p.t <-
+ min(summary(lm)$coefficients[(main.effects+1):
+ (main.effects + DS.parameters),"Pr(>|t|)"])
Although the vast majority of probesets contain 4
probes, transcript clusters containing probesets with
less than 4 probes will give rise to an unbalanced
design. Nevertheless, the t-distribution is almost a
normal distribution for long transcript clusters so the
unbalanced design does not have any practical im-
plications. For shorter transcript clusters, however,
an unbalanced design might be a problem.
The top 10 most differentially spliced genes, sor-
ted by the minimum p-value of their t-tests, appear
in Table 1a. The gene ZAK was validated as dif-
ferentially spliced in [14]. See Figure 2 for the pro-
file plot of KLK10, where the thick lines representing
the mean intensity in each group have been plotted
for easing the interpretation. Note that there is one
measurement per probe in each probeset, typically 4
probes per probeset. How to obtain such plots is de-
scribed in Section 3.5 below. The genes in Figures
2, 3, 4 and 6 were chosen because they span over a
shorter genomic region and show a more clear picture
of the relationship between probesets and exons than
the other genes in the lists of top 10 genes.
A slight variation of ANOSVA is the probeset-
model as implemented in Partek [40] (note that the
probe subscript p has been removed):
yetr = µ+ αe + βt + γet + Ir + Ctr + εetr. (4)
For the probeset-level ANOSVA we used the
probeset level estimates obtained by affyPLM(...,
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mergeGroups = FALSE). After filtering for non-
present or cross-hybridising probesets, and absent
transcript clusters, we were left with 9494 transcript
clusters to study. These clusters are sorted accord-
ing to the minimum p-value of the individual t-test
scores for differential splicing, and the top 10 genes
obtained appear in Table 1b. The genes MMP11,
ZAK and COMP are in the top 10 genes for both the
ANOSVA probe and the ANOSVA probeset models.
Gene TGFBI appears in Figure 3.
FIRMA (Finding Isoforms using Robust Multi-
chip Analysis) was first introduced by Purdom et al.
[30] for the exon array. In presence of differential spli-
cing the model in (1) will not fit and this will show
up in the residuals. The linear model used is the
following:
ypetr = αp + βtr + εpetr, (5)
with αp the probe affinity, βtr the gene-level effect for
chip tr and the error terms εpetr are i.i.d. N(0, σ
2)-
distributed. Note that in contrast to the model in
(3) we do not compute an overall gene-level estimate,
but a gene-level estimate per chip.
As in model (1), there is no treatment/probeset
interaction term, so differential splicing is analysed
probesetwise, using the residuals per probeset e:
rpetr = ypetr − (αˆp + βˆtr), (6)
p = 1, . . . ne, t = 1, . . . , T, r = 1, . . . , R
where αˆp and βˆtr are the estimates of αp and βtr.
The median of the standardized residuals per
probeset per chip is chosen as score statistic:
Fe(tr) =
median
p=1,...,ne
( rpetr
MAD
)
. (7)
The standardization with the median absolute de-
viation (MAD) of the residuals per gene makes the
scores comparable across transcript clusters.
The FIRMA scores are extracted from the plmTr
object obtained in Section 3.2. All probesets and
transcript clusters were analysed by FIRMA, since
it is part of the default aroma.affymetrix workflow.
> firma <- FirmaModel(plmTr)
> fit(firma, verbose = verbose)
> fs <- getFirmaScores(firma)
> firma.scores <- extractDataFrame(fs)
After obtaining the FIRMA scores per probeset per
sample, we proceeded as described in [30]: 1) For each
probeset we took the difference of FIRMA scores for
each of the 10 pairs of normal/cancer samples and 2)
calculated the mean of the 10 differences per probe-
set. Then 3) we ranked the probesets according to
their absolute mean difference: as the scores are com-
parable across transcript clusters, larger average dif-
ferences between the normal and cancer samples will
point at exons more differentially spliced between the
two conditions. The resulting list was filtered to keep
only probesets and transcript clusters that has passed
the filter described in 3.3 above, the code is part of
the .Snw file. In order to get a gene list instead of a
probeset list as in [30] we mapped probesets to tran-
script clusters and then selected the top 10 genes
on the list, see Table 1c. The profile plot of gene
LGALS4 appears in Figure 4. The very high average
difference for this gene is due to a FIRMA score of
830030.8 at probeset 3861578 corresponding to the
tumour sample of replicate 7.
Out of 14 genes investigated for differential splicing
in [14, Table 1], 10 passed our filtering procedure and
were analysed for differential splicing: ACTN1, VCL,
CALD1, SLC3A2, COL6A3, CTTN, FN1, MAST2,
ZAK and FXYD6. The gene ZAK appears in the top
10 genes from ANOSVA probe and ANOSVA probe-
set, but a plot is not produced automatically by the
code because ZAK is not recognised by BioMart. In-
stead, we looked the gene up in PubMed obtaining
the Ensembl ID: ENSG00000091436, and used this
to plot the gene, see Figure 5. The gene COL6A3
appears among the top 100 genes for the ANOSVA
probe and the ANOSVA probeset methods. Gene
ACTN1 is among the top 100 genes for ANOSVA
probeset and it is also the first of Gardina’s genes to
appear in the filtered FIRMA list, at position 154.
3.4.2 Differential gene expression
In this section we analyse differential gene expres-
sion using probe level data. We study two types
of transcript clusters: 1) the ones not included in
the ANOSVA probe analysis above (with only one
probeset or not present in both normal and cancer
groups) and 2) the ones not showing differential spli-
cing (ANOSVA probe p-value above 0.1). The ana-
lysis of group 2) is based on the hierarchical principle:
only look for significant main effects (differential ex-
pression in this case) among those transcript clusters
with no significant interaction terms (differential spli-
cing) [46, p. 427]. In total, we analysed 16231 tran-
script clusters. We fit the following linear model to
those transcript clusters:
ypetr = µ+ αe + βt + Ir + Ctr + εpetr, (8)
where βt is the gene level treatment effect, αe is a
parameter that captures probesets expressed above
or below the overall transcript cluster level and Ir
and Ctr are random effects for patient and chip, re-
spectively.
> aov <-
+ aov(intensity ˜ probeset + treatment +
+ Error(replicate + replicate:treatment))
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Gene symbol min p-value
MMP11 2.98e− 10
SOX9 2.59e− 09
FOXQ1 6.38e− 09
KLK10 3.84e− 08
SYNM 4.53e− 07
PHLDA1 4.85e− 07
ZAK 4.89e− 07
SNTB1 5.33e− 07
COMP 6.85e− 07
XPOT 7.87e− 07
(a) Model: ANOSVA probe.
Gene symbol min p-value
SOX4 9.07e− 15
MMP11 9.48e− 14
ZAK 4.40e− 13
FOXQ1 5.98e− 13
TGFBI 4.83e− 12
UBAP2L 8.17e− 12
COMP 2.87e− 11
SLC2A1 4.16e− 11
CDH11 4.19e− 10
CPXM1 4.47e− 10
(b) Model: ANOSVA probeset.
Gene symbol Average difference
LGALS4 83000.0
HMGCS2 82.9
RPS6KA1 31.8
MUC13 28.2
RPL35 24.5
RPL35A 18.8
SLC39A14 18.2
TGFBI 16.2
COL23A1 15.5
SFT2D2 14.2
(c) Model: FIRMA.
Table 1: Top 10 differentially spliced genes from the
models described in 3.4.1. Tables (a) and (b) show
genes with minumum p-values, table (c) shows genes
with their top scores. Genes highlighted in gray ap-
pear in Figures 2, 3, 4 and 5.
> p.F <-
+ summary(aov)$"Error: Within"[[1]]["treatment",
+ "Pr(>F)"]
The null hypothesis is that the gene expression is
the same in all groups. The top 10 genes, with ad-
justed p-values appear in Table 2. The method used
for adjusting the p-values was Benjamini-Hochberg’s
correction [47] using the function p.adjust(...,
method = "BH"). Only 80 out of 159 genes ap-
pearing in Gardina’s list of genes up- and down-
regulated in tumour [14, Additional file 1] passed our
filters and were analysed for differential gene expres-
sion. Among those analysed, the genes CLDN1, SST,
MUSK, KIAA1199 and SLC30A10 were in the top
100. The gene BEST4 is shown in Figure 6. This
gene is down-regulated in tumour (blue) compared
to normal (red) samples. The thicker lines represent
the mean expression levels in the two groups.
3.5 Gene annotation and visualization
We chose to annotate transcript clusters to genes
using the NetAffx transcript cluster annotation
release 32 specified in Section 3.1 using the
AnnotateGenes() function. Some transcript clusters
present unspecific annotation and have several pos-
Gene symbol p-value
LARGE 0.00287
IL6R 0.00847
RXRG 0.00847
BAI3 0.00968
C1orf175 0.01090
GRIK3 0.01090
BEST4 0.01090
KCNN3 0.01090
PLEKHH2 0.01090
HOXD10 0.01090
Table 2: Top 10 differentially expressed genes from
(8) with corrected p-values. Gene BEST4, high-
lighted in gray, appears in Figure 6.
sible associated gene names. We have decided to re-
move such clusters from our output as we cannot map
them uniquely to a gene and afterwards interpret the
result according to the gene structure.
After gene annotation, the user can select genes for
visual inspection. Visual inspection of candidates for
differential splicing is recommended by Affymetrix as
a way to identify possible false positives [25]. Plots of
gene profiles with integrated genomic information are
obtained using the biomaRt [48] and GenomeGraphs
[49] packages in Bioconductor.
We use bioMart to connect to the latest version of
the Homo Sapiens dataset in Ensembl [50] (Ensembl
genes 68, GRCh37.p8 at the time of writing) and re-
trieve genes by their HGNC symbol [51]. Gene and
exon structures are imported from Ensembl. Gene
and Exon objects are created by makeGene() and
makeTranscript() from GenomeGraphs. We store
expression data and probeset start and stop posi-
tions in an ExonArray object by makeExonArray().
The final plot is created passing a list with the
objects created to the gdPlot(list(exon, gene,
transcript,...)) function.
Our plots show on top the gene HGNC symbol fol-
lowed by (+) for genes on the forward strand and by
(-) for those on the reverse strand. Below, the plot
of probeset intensities appears with vertical lines de-
limiting probesets. Note that for models based on
probe-level data (ANOSVA probe, FIRMA and dif-
ferential expression), the intensities of all probes in
the probeset (1 to 4) are shown. Samples from the
same treatment group appear in the same colour, red
for normal samples and in blue for tumour samples in
this case. Immediately after the profile plot, the gene
model retrieved from Ensembl is shown in orange,
followed by the possible transcript model(s) in blue.
The gene model consists of the exons that appear in
all possible transcript models. Exons (boxes) in the
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gene model are linked by blue lines to the probesets
above, indicating which probeset(s) interrogate which
exon. See Figures 2 to 6.
4 Discussion
The aim of this paper was to give a tutorial on how
to perform a complete and reproducible analysis of
exon array data in R/Bioconductor. We have worked
with three packages: aroma.affymetrix, biomaRt
and GenomeGraphs to go from .CEL files to intens-
ity data, statistical analysis, annotation and visualiz-
ation. The packages were chosen for their flexibility
and easy of integration. We believe that our work-
flow covers a number of analysis variants for the exon
array, including differential splicing analysis at probe
and probeset-level and differential expression analysis
at probe level, and gives the user the opportunity to
focus on all or only some of the aspects of the data
analysis. We make our entire code available so that
other researchers can use it as it is or adapt it to their
needs.
Different Bioconductor packages could have been
used in some of the analysis steps. For example,
xmapcore [54] provides annotation data and cross-
mappings between genetic features as transcript
clusters or exons and Affymetrix probesets. This
package, however, requires the separate installation
of a MySQL database, which makes this a more com-
plex alternative than the one we have chosen. The
xps package [55] could have been used for data pre-
processing and summarization, but it requires the in-
stallation of the ROOT framework [56], and a certain
level of understanding of ROOT files and ROOT trees
is recommended. Our workflow does not require any
prior knowledge beyond R/Bioconductor. Other free
software includes BRB-Array Tools [57], based on R,
C, Fortran and Java, with an Excel front end, and
dChip [58], which is written in Visual C++ and de-
veloped for Windows - though some users have been
able to run it on Mac and Unix computers.
A previous paper on exon arrays [24] suggests a
pragmatic approach and does the analysis piecewise
starting with Affymetrix Power Tools (APT) and
then exporting the data to R. We recognise this is a
fix for the lack of straightforward packages for deal-
ing with the exon array in Bioconductor. However,
it implies working with several pieces of software so
we do not find it fit for reproducible research. Li-
censed software, like Partek [40] or GeneSpring GX
[59], has been used in other studies [60, 22]. In con-
trast to licensed software, R/Bioconductor is free and
available for anyone, it allows the user to control
most analysis options and it enables customizable
and reproducible analyses that are more easily re-
viewed. Still, the aroma.affymetrix package does
not provide the speed of Affymetrix Power Tools or
the licensed software, and it requires more user input.
Nevertheless, with this code and minimal user input,
any dataset can be analysed regarding differential ex-
pression at probe level and differential splicing using
the ANOSVA model.
Differential gene expression could have been ana-
lysed using the gene level estimates obtained from the
plmTr object in other R packages such as limma [53].
Another extension of the workflow could include a
general analysis strategy of the FIRMA scores, which
in this study was tailor-made for a two-treatment
scenario. Besides, the profile plots we obtained with
GenomeGraphs, though highly informative, are diffi-
cult to interpret for genes spanning over a long gen-
omic region, as for example TGFBI in Figure 3 and
ZAK in Figure 5. In the future, it would be inter-
esting to study the flexibility of the output imported
from Ensembl and, for example, remove the intronic
regions from the gene and transcript models.
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